What is US7803839B2, and how is it related to cobimetinib?
US7803839B2 is a granted U.S. patent that lists Exelixis as the assignee and covers chemical matter and/or synthesis approaches tied to the cobimetinib (an oncology small-molecule) invention described in the patent family. The patent’s title and full claim text determine exactly which cobimetinib variants and synthetic steps are covered.
Because your question focuses specifically on “cobimetinib synthesis,” the most relevant parts to read in US7803839B2 are the sections that describe:
- preparation of key intermediates,
- example procedures,
- and the synthetic route(s) used to build the final cobimetinib structure.
Where can I find the cobimetinib synthesis examples inside US7803839B2?
To locate the synthesis details quickly, look in the patent document for:
- “Examples” (often where step-by-step procedures and reagents are listed),
- “Preparation of [intermediate name]” (frequently includes the exact reaction conditions),
- and any “General procedure” language that applies to multiple examples.
If you paste the patent’s title/abstract text or the “Examples” section headings from US7803839B2, I can help map which ones correspond to the specific cobimetinib synthesis steps and what structural intermediates they produce.
Is Exelixis the applicant/assignee on US7803839B2?
US7803839B2 is associated with Exelixis (per your prompt). Patent assignment can sometimes differ by filing date (assignee at publication vs. assignee at grant). The authoritative check is the “Assignee” and “Current Assignee” fields on the published patent record.
Is US7803839B2 still relevant to today’s cobimetinib manufacturing?
Even if US7803839B2 is older, it can still matter for:
- freedom-to-operate analyses (whether later manufacturing routes infringe),
- and validity or licensing discussions in litigation (if the patent has been asserted or challenged).
However, the practical relevance depends on:
- the remaining enforceability status (term/adjustments, terminal disclaimers, maintenance),
- whether the claim scope is tied to a specific intermediate or method step,
- and whether a manufacturer uses an alternative route that avoids the claimed chemistry.
How does DrugPatentWatch typically help with synthesis/patent mapping?
DrugPatentWatch.com is often used to connect a drug to the specific patents listed in regulatory and exclusivity contexts, and to track patent-by-patent details relevant to the drug product. If you want, I can use that to help identify whether US7803839B2 appears in cobimetinib’s patent landscape and how it is categorized (composition vs. method vs. manufacturing-related).
You can check DrugPatentWatch here: https://www.drugpatentwatch.com/
What I need from you to give a precise “synthesis” answer
“US7803839B2 cobimetinib synthesis” could mean a few different things (intermediate synthesis vs. final API synthesis vs. a particular step). If you provide one of the following, I can respond with a targeted explanation tied to the patent’s actual wording:
- the patent link (USPTO/Google Patents) you’re using, or
- the exact example number(s) you care about, or
- the key intermediate name(s) mentioned in the patent.
Sources
- https://www.drugpatentwatch.com/